Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : CYTC - How High Can It Go! -- Ignore unavailable to you. Want to Upgrade?

To: Jayne Furman who wrote (121)	5/6/1998 10:25:00 PM
From: Walter High	Read Replies (1) \| Respond to of 185

Colleagues: I have followed Cytyc almost since its IPO. Every time it has dipped below 20 it has been a buy. I was fortunate to sell at 26 several months ago and have now bought back in at 14 1/2. With the positive news today about the insurance companies and the upgrade coming after the close, I bet we will see more upside tomorrow. I bet we will be back to the 24-28 range by sometime in June. This stock is a traders dream because it moves in such wide swings. My advice is to buy it when it is below 23 and sell it when it is above 28. Walter High

To: Jayne Furman who wrote (121)	5/14/1998 5:07:00 PM
From: Beltropolis Boy	Respond to of 185

ThinPrep Pap Test Clinical Advantages Validated in Large-scale Investigator Sponsored Study May 14, 1998 04:17 PM NEW ORLEANS--(BUSINESS WIRE)--May 14, 1998--An investigator-sponsored, European study of nearly 40,000 patients presented this week at the 46th Annual Clinical Meeting of the American College of Obstetricians and Gynecologists (ACOG), reported that the ThinPrep(R) Pap Test(TM) significantly increased the detection of low-grade and high-grade precancerous cervical lesions. The study also demonstrated a significant improvement in specimen adequacy. . . . The results showed a statistically significant three-fold increase in the detection of both low-grade squamous intraepithelial (LSIL) and high-grade squamous intraepithelial (HSIL) lesions in the cohort with the ThinPrep Pap Test. Biopsy results confirmed the presence of lesions in 94 percent of 150 cases identified as HSIL with the ThinPrep Pap Test. The author also reported a statistically significant increase in the number of specimens classified as satisfactory with the ThinPrep Pap Test (91.9 percent vs 72.2 percent) and a significant reduction in "satisfactory but limited by" (SBLB) specimens. investor.msn.com